+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Physician Perspectives 2017: Biosimilar use in IBD

  • ID: 4655562
  • Report
  • February 2018
  • Region: Global
  • 54 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie
  • Celltrion
  • Janssen
  • MORE
Physician Perspectives 2017: Biosimilar use in IBD

Summary

This Physician Perspectives survey focuses on the use of biosimilar anti-TNFs in IBD.

In the next 12 months, nearly half of physicians stated that they would consider switching Remicade patients (in remission) over to biosimilar IFX. A large proportion of physicians reported that their patients have at least occasionally expressed concern (rated >3) over being switched onto a biosimilar anti-TNF from an originator anti-TNF (67%) or being prescribed a biosimilar anti-TNF (54%). Overall, the majority of physicians agreed that they would require a biosimilar to be designated as interchangeable before considering switching patients from an originator to a biosimilar (67%).

The report includes following topics:
  • Familiarity with biosimilar IFX
  • Expected use of biosimilars - IFX & ADA
  • Concerns with biosimilars
  • Switching & Interchangeability.
Scope
  • Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
  • Physicians interviewed were from 5EU and US countries › This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.
Reasons to buy
  • Qualitative insight from 100 high-prescribing specialists in IBD
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Celltrion
  • Janssen
  • MORE
Executive Summary
Methodology
Survey Results
Demographics
Appendix
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Janssen
  • Celltrion
  • AbbVie
Note: Product cover images may vary from those shown
Adroll
adroll